| Literature DB >> 35602558 |
Qisong Su1,2,3, Moussa Ide Nasser1,2, Jiaming He4, Gang Deng2,5, Qing Ouyang2,5, Donglin Zhuang1,6, Yuzhi Deng2,7, Haoyun Hu2,7, Nanbo Liu1,3, Zhetao Li1,8, Ping Zhu1,2,3,5,7,8,9, Ge Li1,2,3,9.
Abstract
Compared with the central nervous system, the adult peripheral nervous system possesses a remarkable regenerative capacity, which is due to the strong plasticity of Schwann cells (SCs) in peripheral nerves. After peripheral nervous injury, SCs de-differentiate and transform into repair phenotypes, and play a critical role in axonal regeneration, myelin formation, and clearance of axonal and myelin debris. In view of the limited self-repair capability of SCs for long segment defects of peripheral nerve defects, it is of great clinical value to supplement SCs in necrotic areas through gene modification or stem cell transplantation or to construct tissue-engineered nerve combined with bioactive scaffolds to repair such tissue defects. Based on the developmental lineage of SCs and the gene regulation network after peripheral nerve injury (PNI), this review summarizes the possibility of using SCs constructed by the latest gene modification technology to repair PNI. The therapeutic effects of tissue-engineered nerve constructed by materials combined with Schwann cells resembles autologous transplantation, which is the gold standard for PNI repair. Therefore, this review generalizes the research progress of biomaterials combined with Schwann cells for PNI repair. Based on the difficulty of donor sources, this review also discusses the potential of "unlimited" provision of pluripotent stem cells capable of directing differentiation or transforming existing somatic cells into induced SCs. The summary of these concepts and therapeutic strategies makes it possible for SCs to be used more effectively in the repair of PNI.Entities:
Keywords: Schwann cells; directed reprogramming; peripheral nervous system; tissue-engineered nerve graft; transcriptional regulators
Year: 2022 PMID: 35602558 PMCID: PMC9120533 DOI: 10.3389/fncel.2022.865266
Source DB: PubMed Journal: Front Cell Neurosci ISSN: 1662-5102 Impact factor: 5.505
FIGURE 1Overview of the repair process of Schwann cells (SCs) after peripheral nerve injury. (A) Under normal physiological conditions, mature myelinated peripheral nerve processes (yellow) are surrounded by the myelin sheath formed by SCs (green). (B) Axonal rupture and myelin disintegration due to peripheral nerve injury. SCs are activated, dedifferentiate, and transform into the repair phenotype. The involved signaling pathways include transforming growth factor beta (TGF-β), neuroregulin 1 (NGR1), αBC transporter, ErbB2, and extracellular signal receptor-kinase (ERK). (C) Repair SCs proliferate and fill the empty endoneurial canal, working with macrophages to remove axonal and myelin-derived debris; the involved signaling pathways include AMP activated protein kinase (AMPK), mammalian target of rapamycin (mTOR), placental growth factor (PIGF), vascular endothelial growth factor receptor 1 (VEGFR1), and ERK. (D) SCs are arranged along axons to form Büngner bands and secrete neurotrophic factors to improve the microenvironment and guide axon regeneration; the involved regulators include Sox1, N-cadherin, EphB2, Robo1, VEGF, lrp4, Fibrin, and L1. (E) SCs are re-myelinated along the regenerated axons to promote neural information transmission; the involved regulators include NRG1, ErbB2/3, Notch, Krox20, yes-associated protein (YAP), transcriptional enhance factor domain transcription factor 4 (TEAD1), and c-Jun.
FIGURE 2The different processes of myelination of SCs during development and after peripheral nerve injury (PNI). (A) SCs generated from neural crests create myelin sheaths in the PNS. Green represents glial cells and precursors, and orange represents the neural tube and yellow represents neurons and their axons. SCPs are neural crest cells that detach from the neural tube and migrate along the nascent peripheral axons, expressing the early glial markers Mpz, Fabp7, Zfp488, Plp1, Sox10, and forkhead box D3 FOXD3. SCPs differentiate into immature SCs, which, via cytoplasmic extension, enclose the axon bundle. Finally, radial sorting is used to choose a single axon for wrapping. SCs that have been myelinated enclosed axon segments, forming myelin sheaths. (B) Dedifferentiation and remyelination of SCs after PNI. Normal SCs form a myelin sheath around axons with one of four phenotypes: subtype 1 expressing LOC100134871 and Hbb, subtype 2 expressing Cldn19 and Emid1, subtype 3 expressing Timp3 and Col5a3, and subtype 4 expressing Cenpf and Mki67. After PNI, SCs transform into a homogenous phenotype and participate in proliferation and phagocytosis. On the fourth day after injury, 776 lncRNAs were unique to the proliferation of SCs. After day 7, 317 lncRNAs were unique to the remyelination of SCs.
Key signaling pathways involved in migration, proliferation and axon guidance of SCs after PNI.
| Signaling pathways | Factors | Function | References |
| TGF-β | TGF-β, N-cadherin, EphB2, SOX2 | Dedifferentiation, sorting and migration of SCs, axon regeneration | |
| Slit-Robo | Slit,Slit2,Slit3 | Axon pathfinding, migration of SCs | |
| ErbB2 Receptor | NRG1, αBC | Proliferation of SCs, axon wrapping and myelination | |
| Notch and Hippo | Notch, NICD, Krox20, TEAD1, YAP, TAZ | Proliferation and myelination of SCs | |
| ERK | Raf, fibrin, ERK, c-Jun | Dedifferentiation and myelination of SCs. | |
| VEGF | HIF-1α, VEGF | Proliferation and migration of SCs |
TGF-β, transforming growth factor-β; NRG1, Neuregulin 1; αBC, AlphaB-crystallin; Notch, Neurogenic locus Notch homolog protein; HIF-1α, hypoxia inducible factor −1α; VEGF, vascular endothelial growth factor.
FIGURE 3Signaling pathways involved in SC migration, proliferation, and axon guidance in nerve bridges after peripheral nerve injury. N-Cadherin increases the adhesion between SCs, fibroblasts, and endothelial cells, causing SCs to migrate to the outside of the nerve stump and guiding axons to reorient growth at the injury site. Macrophages enter the nerve space and secrete Slit3, which binds with SCs expressing Robo1 to control the formation of correct nerve bridges and promote SC migration and axon guidance. Macrophages in the nerve bridges detect hypoxia and enhance the amount of VEGF-induced blood vessel regeneration, alleviating hypoxia, and acting as an important medium to guide axon regeneration.
FIGURE 4Important factors involved in the application of biomaterials in combination with Schwann cells (SCs) in peripheral nerve regeneration. Matrix components, secreted factors, cell adhesion, substrate stiffness and topographical cues and gradients influence the behavior of SCs on biomaterials, which is crucial for peripheral nerve regeneration. NGF, nerve growth factor; GDNF, glial-derived neurotrophic factor; BDNF, brain-derived neurotrophic factor; NT-3, neurotrophin-3; PDGF, platelet-derived growth factor.
The methods used in recent years to reprogram cells from different sources into iSCs are summarized.
| Original cell | Induction factors | Phenotypic Markers | Animal model | Result | References |
| BMSCs | BME, RA, FSK, rbFGF, PDGF and HRG | p75,S-100,GFAP and O4 | Sciatic nerve injury | The GFP expressing MSCs differentiated into myelin cells and supported the regrowth of nerve fibers within 3 weeks after surgery. |
|
| BMSCs | BME, RA, FSK, bFGF, PDGF and HRG | P0 and MAG | Sciatic nerve injury | ISCs-derived artificial grafts have a strong potential to promote peripheral nerve regeneration and can be used to reconstruct long distance gaps in difficult peripheral nerves. |
|
| BMSCs | BME, RA, FSK, bFGF, PDGF and HRG | PMP22,P0 and MBP | Facial nerve injury | Compared with BMSCs, iSCs provide a faster rate of axon extension and better quality of myelination for peripheral nerve regeneration. |
|
| BMSCs | BME, RA, FSK, bFGF, PDGF and HRG, PROG, insulin and GLUCs. | GFAP, S100B, P0, and PMP22 | Sciatic nerve injury | The combined application of PROG, GLUC and insulin significantly improved the differentiation and culture conditions of classical iSCs, and enhanced the stability of morphology, phenotype and functional characteristics of iSCs |
|
| ADSCs | engineered substrates with imprinted cell-like topographies | S100b, p75 | – | Specific cell-like topography and associated micromechanical cues can directly differentiate ADSCs into Schwann cells. |
|
| ADSCs | BME, RA, FSK, bFGF, PDGF and HRG | GFAP, S100 and p75 | – | Adipose stem cells can transdifferentiate into iSCs, which may be beneficial for the treatment of peripheral nerve injury. |
|
| ADSCs | BME, RA, FSK, bFGF, PDGF and HRG | GFAP, S100 and p75 | Common peroneal nerve injury | DASCs can be used as a substitute for autologous SCs to form myelin sheaths wrapped with axons |
|
| ADSCs | BME, RA, FSK, bFGF, PDGF and HRG | S-100, p75 and integrin β4 | Sciatic nerve injury | DASCs can accelerate nerve conduction velocity, increase nerve fiber density and myelinated/unmyelinated fiber ratio, and rebuild nerves. |
|
| ADSCs | BME, RA, FSK, bFGF, PDGF and HRG, PROG, insulin and GLUCs. | S100B, GFAP, PMP22 and P0 | Sciatic nerve injury | The combined application of PROG, GLUC and insulin significantly improved the differentiation and culture conditions of classical iSCs, and enhanced the stability of morphology, phenotype and functional characteristics of iSCs |
|
| MSCs | electrical stimulation by graphene electrodes | p75,α-S100 and α-S100β | – | MSCs can be transdifferentiated into Schwann cell-like phenotypes by electrical stimulation alone without additional chemical growth factors. |
|
| UCB-MSCs | BME, RA, FSK, bFGF, PDGF and HRG | GFAP and S-100 | – |
| |
| hESCs | N2, glutamine, penicillin, streptomycin, bFGF, FSK, NRG1 | GFAP, S100, HNK1, P75, MBP and PMP-22 | – | HESCs derived neurosphere cells can efficiently differentiate into iSCs with expression of SCs markers. |
|
| Human pluripotent stem cells (hPSCs) | N2, B27, BSA, GlutaMAX, BME, CT 99021, SB431542, NRG1, forskolin, RA, PDGF-BB | S100B, NGFR, EGR2, and MPZ | Sciatic nerve injury | Two small molecules SB431542 (a TGF-β inhibitor) and CT99021 (GSK-3 inhibitor) and NRG1 were used and high-quality multipotent SCPs were produced. SCPs can be effectively differentiated into mature SCs with the functions of secreting GDNF, NGF, BDNF and NT-3, which can promote myelination of rat DRG axons |
|
| Skin fibroblasts | Lentiviral vectors | Erbb2, Erbb3, Cnx32, Pmp22 and Mpz | – | By driving the expression of two transcription factors, Sox10 and Egr2, human fibroblasts can be successfully transformed into iSCs with unique molecules and functions. |
|
| SKIN fibroblasts | Retroviral vectors | S100B | Sciatic nerve injury | Transduction of SOX10 and Krox20 genes directly converts human fibroblasts into functional iSCs. ISCs can form myelin sheath and help mice recover from peripheral nerve injury. |
|
BMSCs, bone marrow mesenchymal cells; BME, beta-mercaptoethanol; RA, retinoic acid; FSK, forskolin; bFGF, basic-fibroblast growth factor PDGF, platelet derived growth factor; HRG, heregulin-beta1; GFP, green fluorescent protein; iSCs, induced Schwann-like cells; PROG, progesterone; GLUCs, glucocorticoids; ADSCs, adipose-derived stem cells; UCB-MSCs, umbilical cord blood-derived mesenchymal stromal cells; hESCs, human embryonic stem cells; NRG1, neuregulin-1; SCs, Schwann cells; MSCs, mesenchymal stem cells; hPSCs, human pluripotent stem cells; GSK-3, glycogen synthase kinase-3; GDNF, glial cell line-derived neurotrophic factor; NGF, nerve growth factor; BDNF, brain-derived neurotrophic factor; NT-3, neurotrophin-3; SCPs, Schwann cell precursors; DRG, dorsal root ganglion.